The population effectiveness of highly active antiretroviral therapy: are good drugs good enough?
about
Social support as a predictor of early diagnosis, linkage, retention, and adherence to HIV care: results from the steps study.Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIVThe Majority of the Pre-Antiretroviral Population Who Were Lost to Follow-Up Stopped Their Care in Freetown, Sierra Leone: A 12-Month Prospective Cohort Study Starting with HIV Diagnosis.Development and validation of a measure for intention to adhere to HIV treatment.The Influence of Trust in Physicians and Trust in the Healthcare System on Linkage, Retention, and Adherence to HIV CareMeasuring retention in HIV care: the elusive gold standard.Missed connections: HIV-infected people never in care.Re-engagement in HIV Care: A Clinical and Public Health PriorityAlcohol consumption as a barrier to prior HIV testing in a population-based study in rural UgandaThe therapeutic implications of timely linkage and early retention in HIV care.Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment.High rates of retention and viral suppression in the US HIV safety net system: HIV care continuum in the Ryan White HIV/AIDS Program, 2011.The 2013 HIV Continuum of Care in Tennessee: Progress Made, but Disparities Persist.Effectiveness of a Peer Navigation Intervention to Sustain Viral Suppression Among HIV-Positive Men and Transgender Women Released From Jail: The LINK LA Randomized Clinical Trial.
P2860
Q34017310-40ACE978-E170-454D-AFF3-DFB12B9392F0Q34104857-E42911F7-E2A8-4B20-9BDC-144C874A8EB4Q35526694-FB8B87E4-E2DE-4748-9EE9-5C95161B4457Q35931363-3BCAB044-A7D7-4596-A0C6-A1E97A0C943BQ36142865-9042E422-671F-4CE3-9838-D7B024A06541Q36385925-16C07E95-EA6D-4D7C-9407-2D2E51F87545Q36428000-7974D115-B4F9-44F0-975D-D06AED8925DBQ36577877-CF88D02F-978A-4F77-8609-194B8781D647Q36856863-6FEF166E-EBE9-4ECD-8BFE-F5FAF5C3914BQ37160636-D4312394-2B4F-48E1-9E13-28598C69A98AQ37322240-4A4EEFE6-E1E0-4EF6-B63C-BB64F4B67F8EQ37442088-1813A81A-40F4-4946-A313-6D6D5A89A451Q38423623-EDC9B90E-6A29-496B-AE35-94A1823CE688Q38765799-B5E44A94-659D-48D3-9791-AAC687876A9EQ54257188-62894E57-46FD-4C49-B647-9FC5EA43284B
P2860
The population effectiveness of highly active antiretroviral therapy: are good drugs good enough?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The population effectiveness o ...... y: are good drugs good enough?
@ast
The population effectiveness o ...... y: are good drugs good enough?
@en
type
label
The population effectiveness o ...... y: are good drugs good enough?
@ast
The population effectiveness o ...... y: are good drugs good enough?
@en
prefLabel
The population effectiveness o ...... y: are good drugs good enough?
@ast
The population effectiveness o ...... y: are good drugs good enough?
@en
P2093
P2860
P1476
The population effectiveness o ...... y: are good drugs good enough?
@en
P2093
Maria E Suarez-Almazor
Richard M Grimes
Thomas P Giordano
P2860
P2888
P304
P356
10.1007/S11904-005-0013-7
P577
2005-11-01T00:00:00Z